Toward imaging of alpha-synuclein with PET

Area of Science:

• Neuroscience
• Radiochemistry
• Molecular Imaging

Background:

• Alpha-synuclein aggregates are key pathological hallmarks of Lewy body diseases.
• Current diagnostic methods for Lewy body diseases lack definitive in vivo biomarkers.
• Positron emission tomography (PET) imaging offers potential for non-invasive visualization of neuropathology.

Purpose of the Study:

• To develop a high-affinity PET tracer for in vivo imaging of alpha-synuclein aggregates.
• To enable early and accurate diagnosis of Lewy body diseases.

Main Methods:

• Development of a novel radiotracer targeting alpha-synuclein.
• Characterization of tracer binding affinity and specificity.
• In vivo imaging studies using positron emission tomography.

Main Results:

• A high-affinity PET tracer for alpha-synuclein was successfully developed.
• The tracer demonstrated specific binding to alpha-synuclein aggregates in preclinical models.
• The tracer shows promise for in vivo imaging of alpha-synuclein pathology.

Conclusions:

• The developed PET tracer represents a significant advancement in imaging alpha-synuclein.
• This tracer has the potential to revolutionize the diagnosis and monitoring of Lewy body diseases.
• Further clinical validation is warranted to assess its diagnostic and therapeutic utility.